Sight Sciences, Inc. (NASDAQ:SGHT) Insider Jeremy B. Hayden Sells 6,922 Shares of Stock

Sight Sciences, Inc. (NASDAQ:SGHT) insider Jeremy B. Hayden sold 6,922 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $2.78, for a total transaction of $19,243.16. Following the transaction, the insider now directly owns 145,091 shares of the company’s stock, valued at approximately $403,352.98. This trade represents a 4.55 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Sight Sciences Trading Up 2.1 %

Shares of NASDAQ:SGHT opened at $2.89 on Wednesday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18. The stock has a market capitalization of $146.70 million, a price-to-earnings ratio of -2.83 and a beta of 2.57. Sight Sciences, Inc. has a 1-year low of $2.67 and a 1-year high of $8.45. The company has a 50 day moving average price of $3.59 and a 200 day moving average price of $5.35.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, November 7th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million during the quarter, compared to analysts’ expectations of $20.41 million. On average, research analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Sight Sciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its stake in Sight Sciences by 47.6% in the 4th quarter. SG Americas Securities LLC now owns 17,622 shares of the company’s stock worth $64,000 after acquiring an additional 5,681 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Sight Sciences by 31.1% in the 2nd quarter. American Century Companies Inc. now owns 35,948 shares of the company’s stock valued at $240,000 after purchasing an additional 8,527 shares during the period. B. Riley Wealth Advisors Inc. lifted its position in shares of Sight Sciences by 5.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock worth $1,174,000 after purchasing an additional 10,000 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Sight Sciences by 40.1% during the second quarter. Rhumbline Advisers now owns 40,811 shares of the company’s stock worth $272,000 after purchasing an additional 11,671 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Sight Sciences by 1.6% during the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after purchasing an additional 12,709 shares during the period. 55.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SGHT. Lake Street Capital cut their price objective on shares of Sight Sciences from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler reiterated a “neutral” rating and issued a $5.50 price objective (down from $6.00) on shares of Sight Sciences in a report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Sight Sciences in a research note on Tuesday, January 14th. Morgan Stanley cut their target price on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating for the company in a research report on Monday, November 11th. Finally, UBS Group began coverage on Sight Sciences in a research report on Friday, December 6th. They set a “buy” rating and a $5.50 price target on the stock. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and a consensus target price of $4.72.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.